|
|
|
| Effect of adjuvant treatment of Huangkui Capsules on urinary albumin excretion rate and oxidative stress in patients with early diabetic nephropathy |
| HE Lifang1 LI Qingke1 XUE Yanyun1 REN Pingxiang2 MA Yuxia2 YAN Shuanghuan3 |
1.Department of Nephrology, Tangshan People’s Hospital, Hebei Province, Tangshan 063000, China；
2.Department of Nephrology, Tangshan Fengrun People’s Hospital, Hebei Province Tangshan 064000, China;
3.Department of Infectious Disease, The Fifth Hospital of Shijiazhuang, Hebei Province, Shijiazhuang 050000, China
|
|
|
|
Abstract Objective To investigate the effect of Huangkui Capsules on urinary albumin excretion rate and oxidative stress in patients with early diabetic kidney disease. Methods A total of 60 patients with stage Ⅳ diabetic nephropathy admitted and diagnosed in Tangshan People’s Hospital of Hebei Province from December 2019 to December 2021 were selected as the study objects. They were divided into control group and observation group by random number table method, with 30 cases in each group. The control group was treated with Valsartan 80 mg once a day, and the observation group was treated with Huangkui Capsules three times a day on the basis of the control group, and observed for sie mouths weeks. The clinical efficacy, urinary protein excretion rate (UARE), blood creatinine (SCr), blood β2-microglobulin (β2-MG), blood superoxide dismutase (SOD), blood malondialdehyde (MDA) and blood glutathione peroxidase (GSH-Px) before and after treatment were compared between the two groups. Results The clinical efficacy of the observation group was better than that of the control group, and the difference was statistically significant (P＜0.05). After treatment, UAER, blood β2-MG, Scr and MDA in two groups were lower than those before treatment, GSH-PX and SOD were higher than before treatment, and UAER, blood β2-MG, Scr and MDA in observation group were lower than control group, while GSH-PX and SOD in observation group were higher than control group, the differences were statistically significant (P＜0.05). Conclusion Huangkui Capsules adjuvant treatment can effectively reduce the levels of UARE, β2-MG and Scr in patients with diabetic kidney disease. The mechanism may be that Huangkui Capsules can inhibit oxidative stress by reducing serum MDA, and increasing SOD and GSH-PX, so as to exert renal protective effect.
|
|
|
|
|
|
[1] Thomas MC，Brownlee M，Susztak K，et al. Diabetic kidney disease [J]. Nat Rev Dis Primers，2015，1：15018.
[2] Sagoo MK，Gnudi L. Diabetic Nephropathy： An Overview[J]. Methods Mol Biol，2020，2067：3-7.
[3] Sawaf H，Thomas G，Taliercio JJ，et al. Therapeutic Advances in Diabetic Nephropathy [J]. J Clin Med，2022，11（2）：378.
[4] An W，Huang Y，Chen S，et al. Efficacy and safety of Huangkui capsule for diabetic nephropathy： A protocol for systematic review and meta-analysis [J]. Medicine（Baltimore），2021，100（42）：e27569.
[5] 王志飞，张强，谢雁鸣.黄葵胶囊治疗慢性肾脏疾病的临床综合评价[J].中国中药杂志，2022，47（6）：1484-1492.
[6] 刘中柱，孔祥静，刘艳姝.黄葵胶囊对慢性肾小球肾炎患者血清Lkn-1和TNF-α水平影响的研究[J].中国中西医结合肾病杂志，2011，12（1）：78-79.
[7] 刘洪，钟陵云，李荣亨.黄葵胶囊治疗糖尿病肾病的疗效观察和机制探讨[J].中国中西医结合肾病杂志，2010，11（7）：633-634.
[8] 赵塔娜，蔡栋梁，苑露丹.黄葵胶囊对阿霉素肾病大鼠肾组织MCP-1表达及对肾组织病理损伤的影响[J].中国实验诊断学，2020，24（4）：667-670.
[9] Gu LF，Ge HT，Zhao L，et al. Huangkui Capsule Ameliorates Renal Fibrosis in a Unilateral Ureteral Obstruction Mouse Model Through TRPC6 Dependent Signaling Pathways [J]. Front Pharmacol，2020，11：996.
[10] Ge J，Miao JJ，Sun XY，et al. Huangkui capsule，an extract from Abelmoschus manihot （L.） medic，improves diabetic nephropathy via activating peroxisome proliferator-activated receptor （PPAR）-α/γ and attenuating endoplasmic reticulum stress in rats [J]. J Ethnopharmacol，2016，189：238-249.
[11] Mogensen CE，Schmitz O. The diabetic kidney：from hyperfiltration and microalbuminuria to end-stage renal failure [J]. Med Clin North Am，1988，72（6）：1465-1492.
[12] 王海燕.肾脏病学[M].北京：人民卫生出版社，2008：159-160.
[13] Reidy K，Kang HM，Hostetter T，et al. Molecular mechanisms of diabetic kidney disease [J]. J Clin Invest，2014， 124（6）：2333-2340.
[14] Li N，Tang H，Wu L，et al. Chemical constituents，clinical efficacy and molecular mechanisms of the ethanol extract of Abelmoschus manihot flowers in treatment of kidney diseases [J]. Phytother Res，2021，35（1）：198-206.
[15] 吴薇，刘莹露，万毅刚，等.黄葵胶囊对早期糖尿病肾脏疾病患者胰岛素抵抗和尿微量白蛋白的多靶点治疗作用[J].中国中药杂志，2020，45（23）：5797-5803.
[16] 刘丹丹，王祥生，王建明，等.虫草制剂联合血管紧张素受体阻滞剂治疗糖尿病肾病的Meta分析[J].世界中西医结合杂志，2020，15（5）：835-840.
[17] 汤力，冯哲，陈香美.虫草制剂联合血管紧张素受体阻滞剂治疗糖尿病肾病的Meta分析[J].解放军医学院学报，2013，34（7）：732-736.
[18] Yang X，Luo M，Jiang Q，et al. Effects of Huangkui Capsule on the Expression of SPARC in the Kidney Tissue of a Rat Model with Diabetic Nephropathy [J]. Curr Gene Ther，2019， 19（4）：211-215.
[19] ?覫stergaard JA，Cooper ME，Jandeleit-Dahm KAM. Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease [J]. J Nephrol，2020，33（5）：917-929.
[20] Hasheminasabgorji E，Jha JC. Dyslipidemia，Diabetes and Atherosclerosis： Role of Inflammation and ROS-Redox- Sensitive Factors [J]. Biomedicines，2021，9（11）：1602.
[21] 范玲燕，卢雪玲.2型糖尿病肾病与血糖波动及氧化应激水平的相关性分析[J].中国当代医药，2020，27（16）：102-105.
[22] 孙智梅，刘妍.重组人红细胞生成素-β注射液对糖尿病肾病腹膜透析患者炎症因子水平及氧化应激水平的影响[J].中国医药科学，2022，12（17）：197-200.
[23] 张文君，孙文早，胡绍波，等.糖尿病肾病患者Mn-SOD基因多态性与肾功能氧化性损伤的相关性[J].临床和实验医学杂志，2022，21（7）：709-712.
[24] Xie C，Wu W，Tang A，et al. lncRNA GAS5/miR-452-5p Reduces Oxidative Stress and Pyroptosis of High-Glucose-Stimulated Renal Tubular Cells [J]. Diabetes Metab Syndr Obes，2019，12：2609-2617.
[25] Li Y，Li Y，Zheng S. Inhibition of NADPH Oxidase 5 （NOX5） Suppresses High Glucose-Induced Oxidative Stress，Inflammation and Extracellular Matrix Accumulation in Human Glomerular Mesangial Cells [J]. Med Sci Monit，2020， 26 ：e919399.
[26] Tong Y，Liu S，Gong R，et al. Ethyl Vanillin Protects against Kidney Injury in Diabetic Nephropathy by Inhibiting Oxidative Stress and Apoptosis [J]. Oxid Med Cell Longev，2019，2019：2129350.
[27] An W，Huang Y，Chen S，et al. Efficacy and safety of Huangkui capsule for diabetic nephropathy： A protocol for systematic review and meta-analysis[J]. Medicine （Baltimore），2021， 100（42）：e27569. |
|
|
|
